Central serous chorioretinopathy (CSC) involves accumulation of fluid beneath the retina. The first-line approach focuses on identifying modifiable contributing factors and allowing a structured period of observation, with the expectation of spontaneous improvement in most acute cases.

Clinical Goal

Spontaneous resolution of subretinal fluid within 3–6 months. Most acute presentations follow this natural course when contributing factors are addressed.

First-Line Approach (partial overview)

Management begins with the identification and removal of modifiable risk factors — corticosteroid exposure is the most commonly implicated. Several systemic and lifestyle conditions may also play a role and are considered alongside corticosteroid status.

An observation period is generally recommended for patients presenting with a first acute episode. The length of this period and the criteria for earlier intervention depend on specific clinical features that are detailed in the full protocol.

The complete structured protocol — covering the full risk factor checklist, observation criteria, and clinical decision points — is available below.

References

DOI: 10.1111/ceo.14201

In all patients with CSC, avoidance of modifiable risk factors should first be emphasised, both at the time of presentation and lifelong.
Most commonly, this involves cessation or avoidance of corticosteroids.
There may be a role in treating systemic hypertension, psychological stress, obstructive sleep apnoea, Helicobacter pylori infection, and ceasing phosphodiesterase-6 inhibitors, but such risk factor modification is yet to be well studied.
Although not verified with high quality evidence, an observation period of 3–4 months is generally accepted in patients presenting with their first episode of acute CSC.
The period of observation may be shorter in cases of bullous or recurrent CSC, or if the patient has high visual demands (including commercial drivers or airline pilots).
Most cases of CSC are acute, with spontaneous resolution of SRF within 3–6 months.

View source ↗

What is the first-line treatment for Central serous chorioretinopathy?

Clinical Goal

First-Line Approach (partial overview)

References